Niels Bergsland1, Robert Zivadinov1,2, Ferdinand Schweser1,2, Jesper Hagemeier1, David Lichter3, Thomas Guttuso3. 1. Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA. 2. Center for Biomedical Imaging, Clinical and Translational Science Institute, University at Buffalo, The State University of New York, Buffalo, New York, USA. 3. Movement Disorder Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.
Abstract
BACKGROUND: Parkinson's disease (PD) is characterized in part by the progressive accumulation of iron within the substantia nigra (SN); however, its spatial and temporal dynamics remain relatively poorly understood. OBJECTIVES: The objective of this study was to investigate spatial patterns and temporal evolution of SN iron accumulation in PD. METHODS: A total of 18 PD patients (mean disease duration = 6.2 years) receiving dopaminergic therapy and 16 healthy controls were scanned with 3T MRI at baseline and 3 years later using quantitative susceptibility mapping, an indirect marker of iron content. Iron was assessed separately in the posterior SN and anterior SN at the ventral and dorsal levels of the SN. The results were corrected for the false discovery rate. RESULTS: A significant group effect was found for the ventral posterior SN (P < .001) and anterior SN (P = .042) quantitative susceptibility mapping as well as significant group x time interaction effects (P = .02 and P = .043, respectively). In addition, a significant intragroup change during 3 years of follow-up was found only in the ventral posterior SN of PD (P = .012), but not healthy controls. No significant effects were detected for any dorsal SN measures. No associations were identified with clinical measures. CONCLUSIONS: We found both cross-sectional and longitudinal SN iron changes to be confined to its more ventral location in PD. Because pathology studies also show the ventral SN to degenerate early and to the greatest extent in PD, the assessment of iron levels by quantitative susceptibility mapping in this area may potentially represent a disease progression biomarker in PD.
BACKGROUND:Parkinson's disease (PD) is characterized in part by the progressive accumulation of iron within the substantia nigra (SN); however, its spatial and temporal dynamics remain relatively poorly understood. OBJECTIVES: The objective of this study was to investigate spatial patterns and temporal evolution of SN iron accumulation in PD. METHODS: A total of 18 PDpatients (mean disease duration = 6.2 years) receiving dopaminergic therapy and 16 healthy controls were scanned with 3T MRI at baseline and 3 years later using quantitative susceptibility mapping, an indirect marker of iron content. Iron was assessed separately in the posterior SN and anterior SN at the ventral and dorsal levels of the SN. The results were corrected for the false discovery rate. RESULTS: A significant group effect was found for the ventral posterior SN (P < .001) and anterior SN (P = .042) quantitative susceptibility mapping as well as significant group x time interaction effects (P = .02 and P = .043, respectively). In addition, a significant intragroup change during 3 years of follow-up was found only in the ventral posterior SN of PD (P = .012), but not healthy controls. No significant effects were detected for any dorsal SN measures. No associations were identified with clinical measures. CONCLUSIONS: We found both cross-sectional and longitudinal SN iron changes to be confined to its more ventral location in PD. Because pathology studies also show the ventral SN to degenerate early and to the greatest extent in PD, the assessment of iron levels by quantitative susceptibility mapping in this area may potentially represent a disease progression biomarker in PD.
Authors: Ashley K Lotfipour; Samuel Wharton; Stefan T Schwarz; V Gontu; Andreas Schäfer; Andrew M Peters; Richard W Bowtell; Dorothee P Auer; Penny A Gowland; Nin P S Bajaj Journal: J Magn Reson Imaging Date: 2011-10-10 Impact factor: 4.813
Authors: Edward Ofori; Ofer Pasternak; Peggy J Planetta; Hong Li; Roxana G Burciu; Amy F Snyder; Song Lai; Michael S Okun; David E Vaillancourt Journal: Brain Date: 2015-05-16 Impact factor: 13.501
Authors: Daniel E Huddleston; Jason Langley; Jan Sedlacik; Kai Boelmans; Stewart A Factor; Xiaoping P Hu Journal: Hum Brain Mapp Date: 2017-02-27 Impact factor: 5.038
Authors: S Reimão; S Ferreira; R G Nunes; P Pita Lobo; D Neutel; D Abreu; N Gonçalves; J Campos; J J Ferreira Journal: Eur J Neurol Date: 2015-10-31 Impact factor: 6.089
Authors: Guangwei Du; Mechelle M Lewis; Christopher Sica; Lu He; James R Connor; Lan Kong; Richard B Mailman; Xuemei Huang Journal: Mov Disord Date: 2018-05-14 Impact factor: 10.338
Authors: Roxana G Burciu; Edward Ofori; Derek B Archer; Samuel S Wu; Ofer Pasternak; Nikolaus R McFarland; Michael S Okun; David E Vaillancourt Journal: Brain Date: 2017-08-01 Impact factor: 13.501